Trang Lam
Internal Medicine · Victorville, CANPI 1891718565
Payments from drug & device makers
Across 120 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$638
- Bayer$385
- AbbVie$343
- Novo Nordisk$231
- Amgen$220
- Lilly USA, LLC$201
- plus $768 from 14 others
What the payments were for
- Food & beverage$2,786100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 27 | $638 |
| Bayer | 17 | $385 |
| AbbVie | 16 | $343 |
| Novo Nordisk | 11 | $231 |
| Amgen | 9 | $220 |
| Lilly USA, LLC | 8 | $201 |
| GSK | 5 | $140 |
| Gilead | 4 | $120 |
| Ironwood Pharmaceuticals, Inc | 3 | $81 |
| Astellas Pharma US Inc | 4 | $78 |
| AstraZeneca | 3 | $75 |
| Merck | 3 | $59 |
| Hikma Pharmaceuticals USA | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $40 |
| Ardelyx, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,786 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 180 | $153,136 |
| VemlidyTenofovir Alafenamide | 56 | $79,564 |
| JanuviaSitagliptin Phosphate | 44 | $40,856 |
| ProliaDenosumab | 15 | $24,345 |
| KerendiaFinerenone | 30 | $23,406 |
| VascepaIcosapent Ethyl | 46 | $16,065 |
| FarxigaDapagliflozin Propanediol | 19 | $15,133 |
| EliquisApixaban | 17 | $11,381 |
| LinzessLinaclotide | 17 | $9,700 |
| Diclofenac Sodium | 55 | $7,452 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,097 |
| Atorvastatin Calcium | 467 | $3,402 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 15 | $2,478 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,423 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 11 | $2,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $638 | $153,136180 claims |
| GileadVemlidy | $120 | $79,56456 claims |
| MerckJanuvia | $59 | $40,85644 claims |
| AmgenProlia | $220 | $24,34515 claims |
| BayerKerendia | $385 | $23,40630 claims |
| AstraZenecaFarxiga | $75 | $15,13319 claims |
| AbbVieLinzess | $343 | $9,70017 claims |
| GSKBreo Ellipta, Shingrix | $140 | $7,28725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Victorville
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.